The White House denies that President Donald Trump received retatrutide through the Food and Drug Administration compassionate use program and says the approved patient is not him.The Food and Drug Administration granted compassionate use access in April to a single 79-year-old whose application was overseen by a senior doctor at the National Institutes of Health and who suffered refractory obesity, obstructive sleep apnea and pulmonary hypertension.STAT News cited three anonymous sources saying top health officials reviewed the request, while the Department of Health and Human Services declined to comment and Eli Lilly confirmed it does not discuss individual compassionate use cases.Donald Trump has a history of using experimental treatments such as
Regeneron and purchased up to $680K of
Eli Lilly stock, and White House spokesperson
Kush Desai dismissed the reporting as baseless.